LAS VEGAS, NV — September 18, 2025 — Leads & Copy — Avant Technologies Inc. and Austrianova have formed a Joint Venture and License Agreement to establish Klothonova, Inc., a Nevada corporation focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells.
Under the agreement, Klothonova will leverage Austrianova’s cell-encapsulation technology to develop treatments targeting Alzheimer’s, heart disease, cancer, kidney disease, other age-related conditions, and longevity. Austrianova will contribute its intellectual property and ‘know-how’ to the venture, while Avant will provide capital and resources.
Klothonova will operate as a 50/50 joint venture, focusing on developing innovative treatments through the over expression of the Klotho protein. This exclusive license will enable Klothonova to address critical medical needs and explore longevity-enhancing solutions globally.
Chris Winter, CEO at Avant Technologies, expressed excitement about partnering with Austrianova. Brian Salmons, CEO of Austrianova, added that the joint venture allows them to combine their technologies with Avant’s resources to accelerate the development of Klotho-based therapies.
Klothonova will prioritize the development of treatments for major indications, with each program independently managed.
Avant Technologies Inc. is an emerging Nevada-based technology company dedicated to advancing innovative technologies and strategic partnerships in the biotech and technology sectors.
Austrianova, based in Singapore, specializes in cell encapsulation, GMP-grade cell products, and cell line development.
Contact: Avant Technologies Inc., info@avanttechnologies.com
Source: Avant Technologies Inc.
